Peripheral Blood Stem Cell TransplantationTransplantation, AutologousHematopoietic Stem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyTransplantation, HomologousGranulocyte Colony-Stimulating FactorCyclophosphamideMelphalanLeukapheresisHematologic NeoplasmsAntigens, CD34Blood Component RemovalTreatment OutcomeStem Cell TransplantationMultiple MyelomaLymphoma, Non-HodgkinMyeloablative AgonistsBusulfanGraft vs Host DiseaseEtoposideBone Marrow TransplantationGraft SurvivalThiotepaHematopoietic Stem CellsAntineoplastic Agents, AlkylatingRemission InductionSalvage TherapyVincristineRecurrenceCarmustineDisease-Free SurvivalCytophagocytosisIfosfamideDoxorubicinCytarabineAmyloidosisAntineoplastic AgentsHodgkin DiseaseStem CellsHematopoiesisNeoplasmsCord Blood Stem Cell TransplantationSurvival RateTransplantation ChimeraRetrospective StudiesTissue DonorsTime FactorsSurvival AnalysisWhole-Body IrradiationInfectionLymphoma, T-CellCarboplatinPOEMS SyndromeHistocompatibilityPlatelet CountPrednisoneImmunosuppressive AgentsHistocompatibility TestingFollow-Up StudiesLeukemia, Myeloid, AcuteDexamethasoneRecombinant ProteinsProspective StudiesTransplantation, IsogeneicVidarabineBlood Cell CountDose-Response Relationship, DrugLeukemiaFeasibility StudiesLymphomaBone Marrow PurgingFatal OutcomeCytomegalovirus InfectionsBlood CellsNeutropeniaGraft vs Leukemia EffectDrug Administration ScheduleMyelodysplastic SyndromesChemotherapy, AdjuvantBreast NeoplasmsPrognosisImmunophenotypingAnemia, AplasticBlood Transfusion, AutologousLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLiver TransplantationLymphocyte DepletionHematologic DiseasesPrecursor Cell Lymphoblastic Leukemia-LymphomaT-LymphocytesLeukocytes, MononuclearBone MarrowOpportunistic InfectionsHistiocytosis, Non-Langerhans-CellLivedo ReticularisCyclosporineHLA Antigens